Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO Sarcoma and Rare Cancers | Future directions for sarcoma screening

David Thomas, PhD, FRACP, The Kinghorn Cancer Centre, Sydney, Australia, discusses the future directions of sarcoma screening. The penetrance of genetic defects in telomere maintenance and chromosome separation is still to be determined, which is crucial for the development of risk prevention strategies. The identification of two key gene mutations could lead to the development of synthetic lethal strategies. Prof. Thomas highlights the need for the inclusion of common variants and structural mutations in the map of genetic variations associated with sarcomas, which is currently being developed. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.